BIOTE CORP -A (BTMD) Stock Fundamental Analysis
USA - NASDAQ:BTMD - US0906831039 - Common Stock
2.93 USD
+0.07 (+2.45%)
2.96 USD
+0.03 (+1.02%)
Taking everything into account, BTMD scores 5 out of 10 in our fundamental rating. BTMD was compared to 192 industry peers in the Pharmaceuticals industry. BTMD has only an average score on both its financial health and profitability. A decent growth rate in combination with a cheap valuation! Better keep an eye on BTMD.
1. Profitability
1.1 Basic Checks
BTMD had positive earnings in the past year.
In the past year BTMD had a positive cash flow from operations.
BTMD had positive earnings in 4 of the past 5 years.
Of the past 5 years BTMD 4 years had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 29.87%, BTMD belongs to the best of the industry, outperforming 98.96% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 51.55%, BTMD belongs to the top of the industry, outperforming 99.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 29.87% | ||
| ROE | N/A | ||
| ROIC | 51.55% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 15.73%, BTMD belongs to the top of the industry, outperforming 90.10% of the companies in the same industry.
BTMD's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 17.79%, BTMD belongs to the top of the industry, outperforming 86.46% of the companies in the same industry.
In the last couple of years the Operating Margin of BTMD has declined.
BTMD has a Gross Margin of 71.89%. This is in the better half of the industry: BTMD outperforms 79.69% of its industry peers.
BTMD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.79% | ||
| PM (TTM) | 15.73% | ||
| GM | 71.89% |
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
2. Health
2.1 Basic Checks
BTMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, BTMD has less shares outstanding
Compared to 1 year ago, BTMD has a worse debt to assets ratio.
2.2 Solvency
BTMD has an Altman-Z score of 2.40. This is not the best score and indicates that BTMD is in the grey zone with still only limited risk for bankruptcy at the moment.
BTMD's Altman-Z score of 2.40 is fine compared to the rest of the industry. BTMD outperforms 67.19% of its industry peers.
The Debt to FCF ratio of BTMD is 4.35, which is a neutral value as it means it would take BTMD, 4.35 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 4.35, BTMD belongs to the best of the industry, outperforming 84.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.35 | ||
| Altman-Z | 2.4 |
ROIC/WACC5.8
WACC8.89%
2.3 Liquidity
BTMD has a Current Ratio of 0.98. This is a bad value and indicates that BTMD is not financially healthy enough and could expect problems in meeting its short term obligations.
BTMD's Current ratio of 0.98 is on the low side compared to the rest of the industry. BTMD is outperformed by 82.29% of its industry peers.
BTMD has a Quick Ratio of 0.98. This is a bad value and indicates that BTMD is not financially healthy enough and could expect problems in meeting its short term obligations.
BTMD has a worse Quick ratio (0.74) than 85.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.74 |
3. Growth
3.1 Past
BTMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 190.00%, which is quite impressive.
The earnings per share for BTMD have been decreasing by -48.53% on average. This is quite bad
BTMD shows a small growth in Revenue. In the last year, the Revenue has grown by 6.38%.
The Revenue has been growing by 12.38% on average over the past years. This is quite good.
EPS 1Y (TTM)190%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%-33.33%
Revenue 1Y (TTM)6.38%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-6.66%
3.2 Future
Based on estimates for the next years, BTMD will show a very strong growth in Earnings Per Share. The EPS will grow by 42.78% on average per year.
BTMD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.82% yearly.
EPS Next Y166.59%
EPS Next 2Y24.94%
EPS Next 3Y24.88%
EPS Next 5Y42.78%
Revenue Next Year-2.93%
Revenue Next 2Y0.89%
Revenue Next 3Y2.93%
Revenue Next 5Y6.82%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 3.37, the valuation of BTMD can be described as very cheap.
Based on the Price/Earnings ratio, BTMD is valued cheaper than 97.92% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.13. BTMD is valued rather cheaply when compared to this.
A Price/Forward Earnings ratio of 8.53 indicates a reasonable valuation of BTMD.
BTMD's Price/Forward Earnings ratio is rather cheap when compared to the industry. BTMD is cheaper than 88.54% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.35, BTMD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.37 | ||
| Fwd PE | 8.53 |
4.2 Price Multiples
BTMD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BTMD is cheaper than 93.23% of the companies in the same industry.
BTMD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BTMD is cheaper than 96.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.19 | ||
| EV/EBITDA | 7.05 |
4.3 Compensation for Growth
BTMD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BTMD may justify a higher PE ratio.
A more expensive valuation may be justified as BTMD's earnings are expected to grow with 24.88% in the coming years.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y24.94%
EPS Next 3Y24.88%
5. Dividend
5.1 Amount
No dividends for BTMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.93
+0.07 (+2.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners64.32%
Inst Owner Change0.17%
Ins Owners9.75%
Ins Owner Change0.43%
Market Cap144.86M
Revenue(TTM)197.19M
Net Income(TTM)31.31M
Analysts81.82
Price Target5.51 (88.05%)
Short Float %3.09%
Short Ratio6.63
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)318.36%
Min EPS beat(2)178.65%
Max EPS beat(2)458.07%
EPS beat(4)3
Avg EPS beat(4)223.56%
Min EPS beat(4)-1.96%
Max EPS beat(4)458.07%
EPS beat(8)5
Avg EPS beat(8)86.5%
EPS beat(12)6
Avg EPS beat(12)-127.37%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.83%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)1.66%
Revenue beat(4)1
Avg Revenue beat(4)-2.07%
Min Revenue beat(4)-4.66%
Max Revenue beat(4)1.66%
Revenue beat(8)2
Avg Revenue beat(8)-2.3%
Revenue beat(12)4
Avg Revenue beat(12)-1.33%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-18.93%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-54.83%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.94%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.86%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.37 | ||
| Fwd PE | 8.53 | ||
| P/S | 0.73 | ||
| P/FCF | 4.19 | ||
| P/OCF | 3.49 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.05 |
EPS(TTM)0.87
EY29.69%
EPS(NY)0.34
Fwd EY11.72%
FCF(TTM)0.7
FCFY23.89%
OCF(TTM)0.84
OCFY28.63%
SpS4.03
BVpS-1.72
TBVpS-2.01
PEG (NY)0.02
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 29.87% | ||
| ROE | N/A | ||
| ROCE | 65.25% | ||
| ROIC | 51.55% | ||
| ROICexc | 80.7% | ||
| ROICexgc | 137.37% | ||
| OM | 17.79% | ||
| PM (TTM) | 15.73% | ||
| GM | 71.89% | ||
| FCFM | 17.39% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-32.05%
ROICexgc growth 5YN/A
ROICexc growth 3Y-33.38%
ROICexc growth 5YN/A
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
F-Score6
Asset Turnover1.9
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.35 | ||
| Debt/EBITDA | 2.98 | ||
| Cap/Depr | 184.76% | ||
| Cap/Sales | 3.45% | ||
| Interest Coverage | 3.69 | ||
| Cash Conversion | 106.02% | ||
| Profit Quality | 110.56% | ||
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.74 | ||
| Altman-Z | 2.4 |
F-Score6
WACC8.89%
ROIC/WACC5.8
Cap/Depr(3y)122.96%
Cap/Depr(5y)152.59%
Cap/Sales(3y)2.04%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)190%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%-33.33%
EPS Next Y166.59%
EPS Next 2Y24.94%
EPS Next 3Y24.88%
EPS Next 5Y42.78%
Revenue 1Y (TTM)6.38%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-6.66%
Revenue Next Year-2.93%
Revenue Next 2Y0.89%
Revenue Next 3Y2.93%
Revenue Next 5Y6.82%
EBIT growth 1Y-11.91%
EBIT growth 3Y-2.97%
EBIT growth 5Y6.11%
EBIT Next Year32.82%
EBIT Next 3Y16.27%
EBIT Next 5Y14.88%
FCF growth 1Y14.31%
FCF growth 3Y8.58%
FCF growth 5Y10.09%
OCF growth 1Y28.77%
OCF growth 3Y10.29%
OCF growth 5Y12.28%
BIOTE CORP -A / BTMD FAQ
Can you provide the ChartMill fundamental rating for BIOTE CORP -A?
ChartMill assigns a fundamental rating of 5 / 10 to BTMD.
What is the valuation status of BIOTE CORP -A (BTMD) stock?
ChartMill assigns a valuation rating of 9 / 10 to BIOTE CORP -A (BTMD). This can be considered as Undervalued.
Can you provide the profitability details for BIOTE CORP -A?
BIOTE CORP -A (BTMD) has a profitability rating of 6 / 10.
What is the expected EPS growth for BIOTE CORP -A (BTMD) stock?
The Earnings per Share (EPS) of BIOTE CORP -A (BTMD) is expected to grow by 166.59% in the next year.
Can you provide the dividend sustainability for BTMD stock?
The dividend rating of BIOTE CORP -A (BTMD) is 0 / 10 and the dividend payout ratio is 0%.